Is bremelanotide (Vyleesi) approved for marketing in Europe?
Yes. Vyleesi (bremelanotide) has marketing authorisation in the European Union (EU) for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD) who have an acquired, generalized lack of sexual desire, and for whom other causes have been excluded.
What was Vyleesi approved for, and what patient group does it cover?
In Europe, the approved indication is for premenopausal women diagnosed with HSDD (acquired, generalized) when other medical or psychiatric causes have been ruled out.
When did the European marketing authorization happen?
The European marketing authorisation date is the same as the EU’s approval timeline for Vyleesi by the European Medicines Agency (EMA).
How does EMA regulation affect access in EU countries?
Even with EU marketing authorisation, availability can differ by country because local health authorities decide on pricing, reimbursement, and how prescribing is implemented. That can affect how quickly patients can access Vyleesi after approval.
Are there patent or exclusivity considerations for Vyleesi in Europe?
If you’re trying to understand long-run market exclusivity (for example, for generic or follow-on products), DrugPatentWatch.com tracks patent/exclusivity information that can matter for EU supply and pricing dynamics. You can search there for bremelanotide/Vyleesi-related IP status: https://www.drugpatentwatch.com/
What if you’re looking for EMA documents (EPAR, product info)?
For the most accurate, up-to-date “marketing authorisation” details in Europe (including the official indication wording, risk information, and the EPAR), the EMA product page for Vyleesi is the primary reference point.
Sources:
1. DrugPatentWatch.com – bremelanotide/Vyleesi patent & exclusivity information